AUS Peptide Supply

The early access event

Black
Friday.

20%OFF

Storewide. Starting now.

Early Black Friday

Your favourites.
An earlier saving.

Get 20% off all APS products. Sale prices are already applied, so you can get straight to shopping.

  • No discount code needed
  • Stacks with volume savings
  • Save up to 32% on eligible quantities
Shop the sale

APS products only. Partner offers excluded. Shipping and payment fees calculated at checkout.

The Research Journal.Peptide science, in perspective.
Evidence dossierPublished Updated Version 1.0

Thymosin Alpha-1 research guide

Defined acetylated 28-residue thymic peptide

Thymosin Alpha-1 sequence identity and clinical evidence, including the corrected TESTS trial, without equating a defined peptide with every thymic preparation.

AUS Peptide Supply editorial team
TA1Tα1thymalfasin

01 · Identity

What the name identifies

Thymosin Alpha-1 is a defined 28-amino-acid peptide with an acetylated amino terminus. The synthetic version is known as thymalfasin. It should be distinguished from the broader thymic fractions used in historical isolation work and from preparations described as Thymalin.

02 · Evidence position

What the literature can support

The identity evidence is specific, but clinical conclusions are condition- and product-dependent. The large TESTS trial did not establish a reduction in 28-day mortality in adults with sepsis. Its 2025 correction should be read with the primary publication rather than using superseded figures.

03 · Study-level map

Evidence and its limits

Analytical identity

Was a specific sequence identified?

The 1977 isolation study characterised a 28-residue peptide within thymosin fraction 5. The PubChem thymalfasin record provides the acetylated reference structure.

Limit: Identifying a reference sequence does not establish the composition or quality of a separate commercial vial.

Human randomised

What did the largest selected sepsis trial establish?

TESTS enrolled 1106 adults and found no clear reduction in its primary 28-day all-cause mortality outcome. The corrected primary hazard ratio is 0.97, with a 95% confidence interval of 0.76 to 1.24.

Limit: Subgroup signals do not replace the overall primary result. This condition-specific trial is not evidence of a universal immune benefit or a test of APS inventory.

Analytical identity

Is Thymalin an interchangeable name?

The defined Thymosin Alpha-1 structure is different in evidentiary status from an unspecified thymic preparation. A preparation requires its own component identification.

Limit: No equivalence should be inferred from both names referring to the thymus.

04 · Analytical context

Questions a batch record should answer

  1. 01Do expected sequence, mass and amino-terminal acetylation agree?
  2. 02Is measured peptide content distinguished from nominal vial mass and chromatographic purity?
  3. 03Does the document identify this sample and its relationship to current inventory?

05 · Boundary conditions

What this record does not establish

  • A change in an immune marker does not itself establish a clinical benefit.
  • Thymic mixtures and defined Thymosin Alpha-1 require different identity assessments.
  • No verified APS CoA is available for the associated product at publication.

Sources checked

  1. 1.
    Thymosin alpha1: isolation and sequence analysis of an immunologically active thymic polypeptide

    Goldstein et al. — Proceedings of the National Academy of Sciences / PubMed · 1977 · Primary study

  2. 2.
    Thymalfasin — PubChem CID 16130571

    NIH PubChem · 2026 · Chemical database

  3. 3.
  4. 4.
    Correction to TESTS: thymosin α1 for sepsis

    BMJ — correction to the primary trial · 2025 · Primary study

Continue through the topic